Raymond James Financial (RJF)

Cash & Short-Term Investments

$19.70B

Quarterly · Period ending: · USD

RJF logo

RJF Cash & Short-Term Investments

Latest reported$19.70B
RJF Quarterly Cash & Short-Term Investments ($242.40M → $19.70B)
High-resolution chart · PNG

RJF cash & short-term investments history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Raymond James Financial Cash & Short-Term Investments — Quarterly (USD)
Period endingCash & Short-Term Investments (USD)
19,700,000,000
19,454,000,000
16,530,000,000
18,277,000,000
16,349,000,000
17,090,000,000
17,764,000,000
19,247,000,000
17,614,000,000
19,012,000,000
19,468,000,000
18,597,000,000
19,097,000,000
19,429,000,000
17,082,000,000
16,071,000,000
17,511,000,000
15,576,000,000
17,480,000,000
16,606,000,000
15,300,000,000
14,800,000,000
13,925,000,000
13,975,000,000
11,816,000,000
15,488,000,000
8,289,000,000
8,101,000,000
7,770,000,000
7,990,000,000
8,209,000,000
7,271,000,000
6,861,364,000
6,972,601,000
7,196,171,000
6,826,679,000
6,021,036,000
5,821,542,000
4,766,940,000
3,693,622,000
4,068,234,000
3,460,602,000
4,199,187,000
4,486,919,000
4,316,987,000
4,555,289,000
4,335,062,000
4,037,218,000
4,704,436,000
4,709,239,000
4,680,456,000
4,710,690,000
4,396,577,000
4,490,354,000
4,494,034,000
4,247,030,000
3,344,174,000
3,667,867,000
2,881,850,000
3,330,713,000
2,644,172,000
2,175,187,000
2,273,482,000
3,955,826,000
1,825,985,000
2,088,649,000
1,813,463,000
5,127,515,000
1,491,845,000
1,730,154,000
2,131,618,000
4,566,289,000
2,209,882,000
2,588,385,000
2,057,738,000
2,444,124,000
1,482,583,000
3,042,303,000
1,806,491,000
1,127,462,000
1,311,563,000
1,420,987,000
1,153,297,000
1,240,812,000
1,246,186,000
1,179,683,000
1,056,708,000
858,684,000
1,023,409,000
1,473,917,000
1,704,826,000
2,152,843,000
2,872,086,000
3,045,251,000
2,954,398,000
2,834,580,000
883,968,000
775,536,000
722,419,000
754,756,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.